Swiss biopharmaceutical company BioVersys’ antibiotic combination, AlpE, has offered bacteria-killing benefits in a mid-stage tuberculosis (TB) study – a development that the company says warrants continued research.
In the 14-day Phase IIa ENABLE trial (NCT06748937), BioVersys set out to evaluate the potential of AlpE – a combination of the anti-TB drug, ethionamide, and novel small molecule, alpibectir – in patients with newly diagnosed, drug-sensitive pulmonary TB. Researchers looked at the potential of AlpE as a standalone treatment, as well as in combination with rifampicin, pyrazinamide and ethambutol (RZE) – acting as a replacement for the antibiotic isoniazid in the pulmonary TB standard-of-care (SOC) HRZE regimen.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Within this study, the results of which were presented at the ongoing Union World Conference on Lung Health in Brazil, all the tested regimens displayed bacteria-killing activity, though their effect was dependent on the dose of ethionamide a patient received.
While researchers did not design the trial to formally compare the effectiveness of each treatment arm, they found that a regimen of 45mg AlpE and 250mg RZE demonstrated numerically similar early bacteria-killing activity to HRZE – a feat which BioVersys suggests highlights the potential of AlpE to replace isoniazid as a treatment option for patients who are resistant to the drug.
On top of AlpE’s promising efficacy, patients also generally tolerated the antibiotic combination well, with BioVersys calling the drug’s safety profile “acceptable” over the 14 days of this study.
BioVersys is developing AlpE through TB collaboration with British pharma giant, GSK. A European public-private partnership, UNITE4TB, also backs the Swiss biopharma. UNITE4TB aims to accelerate clinical trials focused on novel TB treatment regimens as the threat of antimicrobial resistance (AMR) looms.
According to Dr David Barros-Aguirre, GSK’s head of global health medicines R&D, the early ENABLE findings provide further evidence that supports AlpE’s continued evaluation as a potential component of “simpler and more effective” future TB regimens.
“By combining GSK’s science and innovation with the expertise of BioVersys and partners across UNITE4TB, we’re aiming to improve treatment options for people affected by TB,” Barros-Aguirre commented.
Building a new antibiotic arsenal amid AMR surge
In recent years, concerns around AMR have grown, as the chronic and sustained global use of similar drug regimens allows pathogens to acquire immunity to current SOC antimicrobial treatments over a sustained period.
Currently, the World Health Organization (WHO) classifies AMR as a major global health threat – with researchers estimating that bacterial AMR accounted for more than 4.7 million deaths in 2021 alone.
With AMR snowballing at a rapid pace, global health organisations are increasingly pouring funds into antibiotic development programmes, with the US’s Biomedical Advanced Research and Development Authority (BARDA) handing over $482m to help Japanese pharma company Shionogi curb the threat of AMR across America.
Meanwhile, the WHO recently directed antibiotic development to priority pathogens, with the agency specifically focused on severe multidrug-resistant (MDR) gram-negative infections, severe gram-positive infections in immunosuppressed and critically ill patients, and bacterial meningitis.
